

ESM Methods. Methods in studies by Ghouri et al and Iliodromiti et al

Data for liver and abdominal fat depots in studies by Ghouri et al and Iliodromiti et al undertaken at the University of Glasgow has not yet been published and this contains description of methods for data acquisition. Participants in study by Iliodromiti and colleagues were recruited as previously described and published [1]. MRI scans were performed by 3.0 Tesla (Magnetom, Siemens) MRI scanner at BHF Glasgow Cardiovascular research centre, Glasgow, UK. MRI scanner had dedicated transmit/receive coil positioned on participants anterior abdominal wall and plane localiser images were acquired by breath-hold axial T1-weighted images at level of L3-5. Data were acquired by two trained radiologists (Dr Stuart Ballantyne and Dr Jonathan Platt) and analysed with use of sliceOmatic software (version 4.3, TomoVision, Visual Imaging Inc., Canada). Each radiologist analysed scans independently and the inter-observer variation was estimated 2.5% for VAT and 0.4% for SAT. SliceOmatic software performs automatic segmentation of fat depots based on signal intensity cut-offs, but the user needs to review the automatic segmentation process to avoid any incorrect segmentations. The operator has control of sliding threshold but interface gives real time visual feedback on performance of threshold. Results are displayed in pixels and mm² for each compartment measured.

MRS liver fat data was obtained by 30x30x30mm MRS single voxel acquisition at the base of the liver (to minimise effects of respiratory motion) avoiding large vessels and at least one centimetre from the liver edge. Two consecutive spectra were acquired – with echo times (TE) of 144 ms and 35 ms (both with repetition times (TR) of 1500 ms) – in same location

for each participant using the point-resolved spectroscopy (PRESS) sequence. Manufacturers software (SAGE, GE healthcare, Milwaukee) was used to obtain liver fat and water ratios. Peak areas for resonances acquired and hepatic lipid resonances were quantified with reference to water resonance peak correcting for T_1 and T_2 [2]. Results could then be calculated for fat fraction (FF) measured as percentage using equation:

FA – area under fat peak, WA – area under water peak, CA- area under creatinine peak

$$FF \text{ (liver)} = 100 \times FA / (FA + WA)$$

FF for the two different echo times every spectroscopy was different so a mean of the two readings was taken to represent fat percentage. This was done for each liver spectroscopy measurement respectively to calculate fat percentage.

Participants in study by Ghouri and colleagues were recruited as per study previously published and described [3]. MRS was performed for estimation of liver fat with a 1.5 Hdest GE Signa magnetic resonance scanner (GE Healthcare, Milwaukee) using an 8-channel cardiac coil at the Beatson West of Scotland cancer centre, Glasgow, UK. Scott Hanvey (SH), medical physicist, was responsible for performing the scans under the supervision of Dr John Foster (JF) consultant clinical scientist and deputy head for MR physics for NHS Greater Glasgow and Clyde. Consent was undertaken by

trained MRI staff working in the centre and clinical supervision and review of scans was provided by Dr Stuart Ballantyne, Consultant radiologist, Gartnavel General hospital. For analysis of abdominal SAT and VAT depots a T1-weighted single MRI slice was identified at level of L3-5 using plane localiser. Selected MRI image for each participant was then analysed for VAT and SAT volumes as described above using sliceOmatic software (version 4.3, TomoVision, Visual Imaging Inc., Canada). Dr James McLaren (JM) and Dr Stamatina Iliodromiti (SI) analysed images independently using sliceOmatic software and mean of two results was taken as measured value for data by Ghouri and colleagues.

- [1] Iliodromiti S, Ghouri N, Celis-Morales CA, Sattar N, Lumsden MA, Gill JM (2016) Should Physical Activity Recommendations for South Asian Adults Be Ethnicity-Specific? Evidence from a Cross-Sectional Study of South Asian and White European Men and Women. *PloS one* 11(8): e0160024. 10.1371/journal.pone.0160024
- [2] Naressi A, Couturier C, Devos JM, et al. (2001) Java-based graphical user interface for the MRUI quantitation package. *MAGMA* 12(2-3): 141-152
- [3] Ghouri N, Purves D, McConnachie A, Wilson J, Gill JM, Sattar N (2013) Lower cardiorespiratory fitness contributes to increased insulin resistance and fasting glycaemia in middle-aged South Asian compared with European men living in the UK. *Diabetologia* 56(10): 2238-2249. 10.1007/s00125-013-2969-y

ESM Table 1. Demographic and cardiometabolic risk factor profile of South Asians and White Europeans stratified by sex in the unpublished studies by Iliodromiti et al and Ghouri et al.

| | South Asian women | White European women | South Asian men | White European men |
|---|----------------------|----------------------|-------------------|--------------------|
| N | 44 | 55 | 28 | 24 |
| Age (years) | 53.5 (10.3) | 54.8 (7.0) | 49.8 (8.2) | 50.3 (5.9) |
| BMI (kg.m ⁻²) | 27.0 (5.3) | 27.1 (4.5) | 28.5 (4.8) | 27.4 (3.2) |
| Waist (cm) | 83.3 (12.1) | 81.8 (9.9) | 101.1 (12.5) | 96.8 (7.3) |
| Non Smoker (n, %) | 45 (98%) | 49 (89%) | 26 (93%) | 23 (96) |
| Menopause (n, %) | 28 (61%) | 33 (60%) | NA | NA |
| Glucose (mmol.l ⁻¹) | 5.00 [4.60, 5.30] | 5.00 [4.70, 5.20] | 5.25 [4.90, 5.70] | 5.00 [4.80, 5.55] |
| HbA1c (mmol/mol) | 39.0 [36.0, 41.0] | 34.0 [31.0, 37.0] | 37.7 [36.6, 40.2] | 35.5 [34.2, 37.7] |
| HbA1c (%) ^a | 5.72 [5.44, 5.90] | 5.26 [4.99, 5.54] | 5.60 [5.50, 5.83] | 5.40 [5.28, 5.60] |
| Insulin (pmol.l ⁻¹) | 60 [41, 88] | 44 [31, 58] | 91 [58, 118] | 61 [40, 74] |
| HOMA _{IR} ^a | 2.22 [1.50, 3.28] | 1.64 [1.07, 2.18] | 3.36 [2.41, 4.44] | 2.27 [1.39, 2.99] |
| Total Cholesterol (mmol.l ⁻¹) | 5.39 (0.82) | 5.62 (0.74) | 5.33 (0.83) | 5.39 (0.98) |
| HDL-Cholesterol (mmol.l ⁻¹) | 1.46 (0.36) | 1.73 (0.48) | 1.11 (0.17) | 1.27 (0.24) |
| LDL-cholesterol (mmol.l ⁻¹) | 3.29 (0.68) | 3.35 (0.83) | 3.49 (0.71) | 3.44 (0.84) |
| Triacylglycerol (mmol.l ⁻¹) | 1.28 [0.87, 1.72] | 0.90 [0.70, 1.27] | 1.35 [0.98, 2.00] | 1.20 [0.93, 1.68] |
| Systolic blood pressure (mmHg) | 127.4 (14.2) | 127.0 (18.3) | 123.9 (11.9) | 129.3 (12.4) |
| Diastolic blood pressure (mmHg) | 79.2 (10.7) | 78.6 (10.3) | 76.5 (7.0) | 76.8 (6.9) |
| Subcutaneous fat (cm ²) | 243.4 [197.8, 323.7] | 262.4 [190.2, 319.8] | 177.5 (63.6) | 122.7 (38.8) |
| Visceral fat (cm ²) | 109.4 [76.2, 165.6] | 81.5 [56.7, 120.6] | 186.1 (58.3) | 213.9 (63.5) |
| Liver fat (%) | 4.3 [2.0, 9.2] | 2.5 [1.1, 5.9] | 6.92 (2.11) | 7.52 (2.35) |

Values are mean (SD), median [IQR], or n (%).

ESM Table 2. Demographic summary data (summary mean and range) for the studies included in the meta-analyses on subcutaneous and visceral fat.

| | South Asian men | European men | South Asian non-diabetic men | European non-diabetic men | South Asian women | European women | South Asian non-diabetic women | European non-diabetic women |
|---------------------------------|------------------|------------------|------------------------------|---------------------------|-------------------|-----------------|--------------------------------|-----------------------------|
| N | 1156 | 2891 | 615 | 2274 | 697 | 2271 | 402 | 1402 |
| Age (years) | 48.2 (22 to 69) | 49.3 (22 to 70) | 42 (22 to 58) | 42.3 (22 to 62) | 51.6 (24 to 68) | 53.4 (25 to 70) | 46.5 (24 to 58) | 47.6 (25 to 62) |
| BMI (kg.m ⁻²) | 25.6 (21 to 28) | 26.3 (22 to 28) | 25.1 (21 to 27) | 25.5 (22 to 27) | 26.3 (22 to 29) | 27.2 (23 to 29) | 25.2 (22 to 27) | 26.3 (23 to 29) |
| Glucose (mmol.l ⁻¹) | 5.3 (5.1 to 5.4) | 5.1 (5.0 to 5.3) | 5.3 (5.1 to 5.4) | 5.1 (5.0 to 5.3) | 5.0 (4.8 to 5.2) | 4.9 (4.8 to 5) | 5.0 (4.8 to 5.2) | 4.9 (4.8 to 5) |
| Insulin (pmol.l ⁻¹) | 59 (43 to 91) | 51 (29 to 75) | 62 (42 to 90) | 45 (30 to 63) | 56 (46 to 66) | 53 (44 to 72) | 55 (46 to 66) | 53 (44 to 72) |

n = 6 and 5 out of 9 studies had summary data on glucose and insulin levels respectively for men and 5 out of 8 for women

ESM Table 3. Demographic summary data (summary mean and range) for the studies included in the meta-analyses on liver fat.

| | South Asian men | European men | South Asian non-diabetic men | European non-diabetic men | South Asian women | European women | South Asian non-diabetic women | European non-diabetic women |
|---------------------------------|------------------|------------------|------------------------------|---------------------------|-------------------|-----------------|--------------------------------|-----------------------------|
| N | 677 | 2394 | 611 | 2328 | 575 | 2076 | 509 | 2001 |
| Age (years) | 37.9 (22 to 58) | 38 (22 to 58) | 36.7 (22 to 58) | 36.2 (22 to 58) | 50.8 (38 to 58) | 52.7 (35 to 62) | 52.1 (38 to 58) | 53.2 (35 to 62) |
| BMI (kg.m ⁻²) | 25.3 (21 to 28) | 25.8 (22 to 28) | 24.9 (21 to 27) | 25.4 (22 to 28) | 26.4 (26 to 28) | 27.5 (27 to 29) | 26 (26 to 27) | 27.1 (27 to 29) |
| Glucose (mmol.l ⁻¹) | 5.3 (5.1 to 5.4) | 5.1 (5.0 to 5.3) | 5.3 (5.1 to 5.4) | 5.1 (5.0 to 5.3) | 5.1 (4.9 to 5.2) | 4.9 (4.8 to 5) | 5.1 (4.9 to 5.2) | 4.9 (4.8 to 5) |
| Insulin (pmol.l ⁻¹) | 63 (43 to 91) | 51 (29 to 75) | 66 (42 to 90) | 46 (30 to 63) | 54 (46 to 62) | 48 (44 to 53) | 52 (46 to 60) | 47 (44 to 49) |

n = 6 out of 7 studies had summary data on glucose and insulin levels for men and 4 out of 5 for women

ESM Table 4. Study-level risk of bias for studies of VAT/SAT using a preliminary version of the ROBINS-E tool

| Studies | Confounding | Participant selection | Measurement of exposure | Departures from exposures | Missing data | Measurement of outcomes | Selection of reported results | Overall study-level bias |
|-------------------------------|-------------------------|-----------------------|-------------------------|---------------------------|--------------|-------------------------|-------------------------------|--------------------------|
| Anand et al [12] | Moderate ² | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| Bakker et al [32] | Low | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| Chandalia et al [13] | Low | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| Eastwood et al [21] | Serious ^{1,3} | Low | Low | Low | Low | Moderate ⁴ | Low | Serious |
| Lear et al [22-23] | Moderate ² | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| Shah et al [28] | Moderate ^{1,2} | Low | Low | Low | Low | Moderate ^{4,5} | Low | Moderate |
| Szuskiewicz-Garcia et al [31] | Moderate ² | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| UK Biobank | Low | Low | Low | Low | Low | Low | Low | Low |
| Ghouri et al | Low | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |
| Iliodromiti et al | Low | Low | Low | Low | Low | Moderate ⁴ | Low | Moderate |

¹men not matched for BMI, ²women not matched for BMI, ³participants with diabetes included, ⁴non-blinded measurement of outcome or unclear whether measurement was blinded, ⁵different MRI scanner used at different study sites

ESM Table 5. Study-level risk of bias for studies of liver fat using a preliminary version of the ROBINS-E tool

| Studies | Confounding | Participant selection | Measurement of exposure | Departures from exposures | Missing data | Measurement of outcomes | Selection of reported results | Overall study-level bias |
|---------------------|-------------------------|-----------------------|-------------------------|---------------------------|--------------|-------------------------|-------------------------------|--------------------------|
| Anand et al [12] | Moderate ² | Low | Low | Low | Low | Moderate ³ | Low | Moderate |
| Dick et al [24] | Low | Low | Low | Low | Low | Moderate ³ | Low | Moderate |
| Petersen et al [25] | Low | Low | Low | Low | Low | Moderate ³ | Low | Moderate |
| Shah et al [28] | Moderate ^{1,2} | Low | Low | Low | Low | Moderate ^{3,4} | Low | Moderate |
| UK Biobank | Low | Low | Low | Low | Low | Low | Low | Low |
| Ghouri et al | Low | Low | Low | Low | Low | Moderate ³ | Low | Moderate |
| Iliodromiti et al | Low | Low | Low | Low | Low | Moderate ³ | Low | Moderate |

¹men not matched for BMI, ²women not matched for BMI, ³non-blinded measurement of outcome or unclear whether measurement was blinded, ⁴different MRI scanner used at different study sites


ESM Table 6. GRADE certainty of evidence for studies included in meta-analysis

| | | Quality assessment | | | | | Overall Certainty |
|---------------------------------|---|-----------------------------------|--|------------|-----------------------------|--|----------------------|
| | Number of studies (No of participants) | Study limitations ¹ | Consistency | Directness | Precision ² | Publication bias | |
| Abdominal fat male studies | 9 (4047) | Serious limitations | Inconsistent results with high heterogeneity | Direct | No important imprecision | Possible bias due to asymmetry on funnel plots for subcutaneous fat (not visceral fat) | Low |
| Abdominal fat female studies | 8 (2968) | Serious limitations | Inconsistent results with high heterogeneity | Direct | No important imprecision | Possible bias due to asymmetry of funnel plots | Low |
| Liver fat male studies | 7 (3071) | Serious limitations | Inconsistent results with high heterogeneity | Direct | No important imprecision | Unlikely due to symmetry of funnel plots | Low |
| Liver fat female studies | 5 (2651) | Serious limitations | Moderate heterogeneity | Direct | No important imprecision | Unlikely due to symmetry of funnel plots | Low |


¹study limitations include differences in BMI between groups in some studies, including of participants with diabetes in one study, and non-blinding of outcome assessors in all studies. In sensitivity analyses excluding studies which included patients with diabetes, and only including studies where BMI was matched, the overall findings were unchanged.

² large number of participants with consistent results and narrow CI in random effects analysis

A




B




ESM Fig 1. Standardised mean differences in subcutaneous (SAT, A), and visceral (VAT, B) in South Asian versus white European men in studies including no participants with diabetes.

A




B




ESM Fig 2. Standardised mean differences in subcutaneous (SAT, A), and visceral (VAT, B) in South Asian versus white European women in studies including no participants with diabetes.


A



B




C




ESM Fig 3. Standardised mean differences in subcutaneous (SAT, A), visceral (VAT, B) and liver fat (C) in South Asian versus White European men in studies with matched BMI.


A



B




C




ESM Fig 4. Standardised mean differences in subcutaneous (SAT, A), visceral (VAT, B) and liver fat (C) in South Asian versus White European women in studies with matched BMI.

A




B




ESM Fig 5. Standardised mean differences in subcutaneous fat (SAT) in South Asian versus White European men in studies using MRI (A) and CT (B) as the assessment tool.

A




B




ESM Fig 6. Standardised mean differences in visceral (VAT) in South Asian versus White European men in studies using MRI (A) and CT (B) as the assessment tool.

A




B




ESM Fig 7. Standardised mean differences in subcutaneous fat (SAT) in South Asian versus White European women in studies using MRI (A) and CT (B) as the assessment tool.

A




B




ESM Fig 8. Standardised mean differences in visceral (VAT) in South Asian versus White European women in studies using MRI (A) and CT (B) as the assessment tool.


A: SAT men




B: SAT women




C: VAT men




D: VAT women



E: Liver fat men



F: Liver fat women



ESM Fig 9. Funnel plots assessing the risk of publication bias for comparison of subcutaneous (SAT; men A, women B), visceral (VAT; men C, women D) and liver (men E, women F) fat in studies of men and women.